An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Expanded access; Therapeutic Use
- 06 Nov 2019 Status changed from recruiting to completed.
- 07 Feb 2019 Status changed from suspended to recruiting.
- 22 May 2018 Status changed from recruiting to suspended.